|Title of the trial||Diagnosis|
|An international randomised trial of additional treatments for COVID-19 in hospitalised patients who are all receiving the local standard of care||COVID-19|
|The efficacy and safety of Eftilagimod Alpha Treatment by immune modulation in COVID-19 disease (EAT COVID trial)||COVID-19|
|An adaptive Phase 2/3, randomized, open-label study assessing efficacy and safety of hydroxychloroquine for hospitalized patients with moderate to severe COVID-19||COVID-19|
|Hydroxychloroquine and Azithromycin for Treatment of COVID-19: An Open Label, Randomized, Controlled Study to Evaluate the Combination Therapy in Patients with SARS-CoV-2 Infection||COVID-19|
|Azithromycin added to Hydrochloroquine in Patients Admitted to Intensive Care due to Coronavirus Disease 2019 (COVID-19) - Randomised Controlled Trial||COVID-19|
2010 © SÚKL. Šrobárova 48, 100 41 Praha 10, +420 272 185 111, posta@suklcz.